Results 31 to 40 of about 28,123 (301)

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy

Molecular Therapy: Methods & Clinical Development, 2017
Current therapies against hepatitis B virus (HBV) do not reliably cure chronic infection, necessitating new therapeutic approaches. The T cell response can clear HBV during acute infection, and the adoptive transfer of antiviral T cells during bone ...
Robert L. Kruse, Thomas Shum, Xavier Legras, Mercedes Barzi, Frank P. Pankowicz, Stephen Gottschalk, Karl-Dimiter Bissig   +6 more
doaj   +1 more source

Chemical generation of bispecific antibodies [PDF]

Proceedings of the National Academy of Sciences, 2010
Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufacturing complexity.
Jie Huang, Bryan Oates, Curt W. Bradshaw, Michael J. Shields, Bin Liu, Richard A. Lerner, Joselyn Del Rosario, Crystal Hagen, Dingguo Liu, Lingna Li, Ping Jin, Michelle Parish, Robert E. Murphy, Gary Woodnutt, Jing-Yu Lai, Joel Desharnais, Marla J. Matin, Zemeda W Ainekulu, Abhijit Bhat, Nancy Levin, Venkata Doppalapudi, Rodney W. Lappe   +21 more
openaire   +3 more sources

Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor‐adapted non‐small cell lung cancer cell lines

FEBS Open Bio, EarlyView.
Phenotypic plasticity in a newly established set of EGFR inhibitor‐adapted NSCLC cell lines during adaptation and in established cell lines. Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib ...
Tharsagini V. Nanthaprakash, Campbell W. Gourlay, Ina Oehme, Michelle D. Garrett, Jindrich Cinatl Jr, Mark N. Wass, Martin Michaelis   +6 more
wiley   +1 more source

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells

Frontiers in Oncology, 2019
Hodgkin Lymphoma (HL) is a malignancy that frequently affects young adults. Although, there are effective treatments not every patient responds, necessitating the development of novel therapeutic approaches, especially for relapsed and refractory cases ...
Sakthi Rajendran, Sakthi Rajendran, Yating Li, Yating Li, Evelyn Ngoh, Hiu Yi Wong, Hiu Yi Wong, Man Si Cheng, Man Si Cheng, Cheng-I Wang, Herbert Schwarz, Herbert Schwarz   +11 more
doaj   +1 more source

CDR loop interactions can determine heavy and light chain pairing preferences in bispecific antibodies

mAbs, 2022
As the current biotherapeutic market is dominated by antibodies, the design of different antibody formats, like bispecific antibodies, is critical to the advancement of the field.
Monica L. Fernández-Quintero, Katharina B. Kroell, Lukas J. Grunewald, Anna-Lena M. Fischer, Jakob R. Riccabona, Klaus R. Liedl   +5 more
doaj   +1 more source

Microphysiological Systems for Comorbidity Studies: Chronic Kidney Disease and Osteoarthritis

Advanced Healthcare Materials, EarlyView.
This review highlights the potential of organ‐on‐a‐chip systems for studying comorbidities, using chronic kidney disease (CKD) and osteoarthritis (OA) as examples. It summarizes recent advances in kidney‐on‐a‐chip and joint‐on‐a‐chip models and discusses their current and potential application in investigating CKD, OA, and CKD‐OA comorbidity, aiming to
Mingying Han, Weiping Lin, Yuanxiong Cao, Patricia Murray, Bettina Wilm, Stephen J McWilliam, Jude Curran, Ruoxiao Xie   +7 more
wiley   +1 more source

Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. [PDF]

PLoS ONE, 2013
In hemophilia A, routine prophylaxis with exogenous factor VIII (FVIII) requires frequent intravenous injections and can lead to the development of anti-FVIII alloantibodies (FVIII inhibitors).
Zenjiro Sampei, Tomoyuki Igawa, Tetsuhiro Soeda, Yukiko Okuyama-Nishida, Chifumi Moriyama, Tetsuya Wakabayashi, Eriko Tanaka, Atsushi Muto, Tetsuo Kojima, Takehisa Kitazawa, Kazutaka Yoshihashi, Aya Harada, Miho Funaki, Kenta Haraya, Tatsuhiko Tachibana, Sachiyo Suzuki, Keiko Esaki, Yoshiaki Nabuchi, Kunihiro Hattori   +18 more
doaj   +1 more source

Self‐Assembling Multi‐Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma

Advanced Healthcare Materials, EarlyView.
A novel modular T‐cell engager platform, MATCH, is developed for personalized multiple myeloma therapy. MATCH uses complementary oligonucleotide‐linked Fab’ fragments to enable flexible targeting of MM antigens and controlled T‐cell activation. The system shows potent, antigen‐specific cytotoxicity in vitro and in vivo, highlighting its potential for ...
Shannuo Li, Jiahui Li, Hasan Al Faruque, Paul Shami, Birgit Knoechel, Jens Lohr, Douglas Sborov, Jiyuan Yang, Jindřich Kopeček   +8 more
wiley   +1 more source

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Experimental Hematology & Oncology, 2017
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li, Kongming Wu   +6 more
doaj   +1 more source

CLEC5a-directed bispecific antibody for effective cellular phagocytosis

mAbs, 2022
While antibody-dependent cellular phagocytosis mediated by activating Fcγ receptor is a key mechanism underlying many antibody drugs, their full therapeutic activities can be restricted by the inhibitory Fcγ receptor IIB (FcγRIIB).
Vivekananda Kedage, Diego Ellerman, Mingjian Fei, Wei-Ching Liang, Gu Zhang, Eric Cheng, Juan Zhang, Yongmei Chen, Haochu Huang, Wyne P. Lee, Yan Wu, Minhong Yan   +11 more
doaj   +1 more source